Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease
Experimental Eye Research · 2026-06 · 267 · 110982
DOI: 10.1016/j.exer.2026.110982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026-06. Verfasst von Farha Husain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, United States. Hauptthemen laut MEDLINE: Metformin, Graves Ophthalmopathy, Hyaluronic Acid, Hypoglycemic Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, Research to Prevent Blindness, National Institutes of Health.
Abstract (Originalsprache)
Thyroid eye disease (TED) is characterized by fibroblast-driven inflammation and extracellular matrix expansion, which contribute to orbital congestion and proptosis. Platelet-derived growth factor-β (PDGFβ) promotes hyaluronan (HA) synthesis and cytokine production in orbital fibroblasts (OFs); however, whether metabolic modulation can counteract this pathway is unknown. We tested whether metformin, an indirect activator of AMP-activated protein kinase (AMPK), attenuates PDGFβ signaling in TED OFs. Primary OFs from 14 TED and 4 non-TED donors were treated with PDGFβ with or without metformin or the direct AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). PDGFβ elicited markedly greater HA and cytokine responses in TED OFs than in non-TED OFs and suppressed AMPK phosphorylation. Metformin treatment restored AMPK phosphorylation, reduced HA accumulation (∼2.3-3.1-fold), and decreased IL-6 and IL-8 production. AICAR produced similar AMPK-dependent effects. Mechanistically, metformin attenuated PDGFβ-driven activation of the phosphoinositide 3-kinase (PI3K)-AKT-forkhead box O1 (FoxO1)-nuclear factor kappa B (NF-κB) axis, a pro-inflammatory and pro-survival cascade. These data identify PDGFβ-mediated AMPK suppression as a pathogenic mechanism in TED fibroblasts and demonstrate that AMPK reactivation reduces pro-fibrotic and inflammatory signals. Together, these findings support the therapeutic repurposing of metformin in TED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, United States.
- Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States.
- Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, United States; Center for Visual Sciences, University of Rochester Medical Center, Rochester, NY, United States.
- Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, United States; Center for Visual Sciences, University of Rochester Medical Center, Rochester, NY, United States; Department of Environmental Me…
Förderung
- NEI NIH HHS
- Research to Prevent Blindness
- National Institutes of Health
- National Eye Institute
Zitieren
APA
Husain, F., Patrick, C. C., Roztocil, E., Feldon, S. E., & Woeller, C. F. (2026). Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease. Experimental Eye Research, 267, 110982. https://doi.org/10.1016/j.exer.2026.110982
Vancouver
Husain F, Patrick CC, Roztocil E, Feldon SE, Woeller CF. Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease. Experimental Eye Research. 2026;267:110982. doi:10.1016/j.exer.2026.110982
BibTeX
@article{Husain2026,
author = {Husain, Farha and Patrick, Charkira C and Roztocil, Elisa and Feldon, Steven E and Woeller, Collynn F},
title = {Metformin inhibits PDGFβ signaling to suppress hyaluronan and cytokine production in thyroid eye disease},
journal = {Experimental Eye Research},
year = {2026},
volume = {267},
pages = {110982},
doi = {10.1016/j.exer.2026.110982}
}
EUVIMED